Its agonists, TZDs, as insulin sensitizers, are commonly used for the treatment of T2DM, which also fulfills a beiging effect (Ohno et al., 2012; Qiang et al., 2012; Wu et al., 2021). This evidence concerns the gene INS and type 2 diabetes mellitus.